Drug Approval | January 24, 2025
Shilpa Pharma Lifesciences received CEP from EDQM for API, Teriflunomide
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
The President said that there is a need to spread more and more awareness regarding the causes, diagnosis and treatment of cancer
Subscribe To Our Newsletter & Stay Updated
